New data at CROI 2025 show zero cases of HIV acquisition reported with Apretude (cabotegravir long-acting (CAB LA) for PrEP) in varied clinical settings and populations in two implementation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results